138006-41-4|3-Bromo-2,5-dichloropyridine| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 138006-41-4 ] Purity: 95% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 138006-41-4 ]

CAS No. :	138006-41-4
Formula :	C₅H₂BrCl₂N
M.W :	226.89
SMILES Code :	BrC1=CC(=CN=C1Cl)Cl
MDL No. :	MFCD06659484
InChI Key :	CDBHWRZEXFQNBI-UHFFFAOYSA-N
Pubchem ID :	12901596

Safety of [ 138006-41-4 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Computational Chemistry of [ 138006-41-4 ] Show Less

Physicochemical Properties

Num. heavy atoms	9
Num. arom. heavy atoms	6
Fraction Csp3	0.0
Num. rotatable bonds	0
Num. H-bond acceptors	1.0
Num. H-bond donors	0.0
Molar Refractivity	41.96
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	12.89 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	2.06
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	3.17
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	3.15
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	2.44
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	3.39
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	2.84

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-3.74
Solubility	0.0416 mg/ml ; 0.000183 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-3.11
Solubility	0.176 mg/ml ; 0.000774 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-4.12
Solubility	0.0174 mg/ml ; 0.0000766 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Moderately soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	Yes
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-5.43 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	1.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	1.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.76

Application In Synthesis of [ 138006-41-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 138006-41-4 ]

[ 138006-41-4 ] Synthesis Path-Downstream 1~35

1
[ 137628-16-1 ]
[ 138006-41-4 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,1998,vol. 8,p. 2777 - 2782.
[2]Journal of Organic Chemistry,1992,vol. 57,p. 1930 - 1933.

2
[ 71171-66-9 ]
[ 138006-41-4 ]
[ 138006-42-5 ]

References: [1]Journal of Organic Chemistry,1992,vol. 57,p. 1930 - 1933.

3
[ 138006-41-4 ]
[ 208516-15-8 ]
[ 217090-24-9 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,1998,vol. 8,p. 2777 - 2782.

4
[ 4214-79-3 ]
[ 138006-41-4 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,1998,vol. 8,p. 2777 - 2782.

5
[ 138006-41-4 ]
etoricoxib [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,1998,vol. 8,p. 2777 - 2782.

6
[ 138006-41-4 ]
N-tert-Butyl-4-(5-chloro-6'-methyl-[2,3']bipyridinyl-3-yl)-benzenesulfonamide [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,1998,vol. 8,p. 2777 - 2782.

7
[ 1072-98-6 ]
potassium nitrite [ No CAS ]
[ 138006-41-4 ]

References: [1]Journal of Organic Chemistry,1992,vol. 57,p. 1930 - 1933.

8
[ 26163-03-1 ]
[ 138006-41-4 ]

References: [1]Journal of Organic Chemistry,2016,vol. 81,p. 4576 - 4587.
[2]Journal of Organic Chemistry,1992,vol. 57,p. 1930 - 1933.

9
[ 138006-41-4 ]
[ 126642-39-5 ]

References: [1]Journal of Organic Chemistry,1992,vol. 57,p. 1930 - 1933.

10
[ 138006-41-4 ]
[ 138126-72-4 ]

References: [1]Journal of Organic Chemistry,1992,vol. 57,p. 1930 - 1933.

11
[ 138006-41-4 ]
[ 138006-44-7 ]

References: [1]Journal of Organic Chemistry,1992,vol. 57,p. 1930 - 1933.

12
[ 138006-41-4 ]
[ 138006-43-6 ]

References: [1]Journal of Organic Chemistry,1992,vol. 57,p. 1930 - 1933.

13
[ 137628-16-1 ]
[ 138006-41-4 ]

Yield	Reaction Conditions	Operation in experiment
81.76 g (89%)	With trichlorophosphate; In N,N-dimethyl-formamide;	EXAMPLE 3 3-Bromo-2,5-dichloropyridine To a solution of 3-bromo-5-chloropyridin-2-one (84.3 g, 0.404 mol) in DMF (100 mL) was added POCl3 (56.5 mL, 0.61 mol) via dropping funnel over 3 hours at room temperature. The resulting black solution was then heated to 70 C. and allowed to stir for 3 days. After cooling to room temperature, the solution was poured into 1 L of ice/water, filtered, and the solid dried in a vacuum oven to provide 81.76 g (89%) of the desired 3-bromo-2,5-dichloropyridine as an off-white solid, m.p. 39-41 C.: IR(CHCl3) 3867, 3663, 2989, 2734, 1812, 1606, 1547, 1400, 1366, 1230, 1155, 1129, 1074, 1027, 894, 658, 563 cm-1; 1 H NMR (300 MHz, CDCl3) delta 8.0 (d, 1H, J=2.2 Hz), 8.35 (d, 1H, J=2.2 Hz); 13 C NMR (CDCl3) delta 120.43, 130.74, 141.46, 146.64, 148.99; exact mass calculated for C5 H2 NBrCl2 =224.8748; high resolution mass spec. 224.8764.

References: [1]Patent: US5068333,1991,A .

14
[ 138006-41-4 ]
[ 59782-85-3 ]

Yield	Reaction Conditions	Operation in experiment
	With n-butyllithium; carbon dioxide; In petroleum; di-isopropyl ether; water;	Reference Example 9 A solution of <strong>[138006-41-4]3-bromo-2,5-dichloropyridine</strong> (10g) in diisopropyl ether was added dropwise to a stirred solution of n-butyllithium (2.5 M in hexanes, 17.7ml) in diisopropyl ether at -70oC under an inert atmosphere so that the reaction temperature did not exceed -68oC. An excess of solid carbon dioxide was then added to the suspension and the mixture was stirred for 2 hours (excess carbon dioxide evaporates, temperature reaches 10oC.). Ice/water was added, the mixture was stirred. The layers were separated. The aqueous layer was acidified to pH 2 with concentrated hydrochloric acid. The resulting precipitate was extracted into diethyl ether. The ether extracts were washed with water, dried (magnesium sulphate) and evaporated to yield a solid which was triturated in light petroleum to yield 2,5-dichloronicotinic acid as a cream solid (7.04g), m.p. 160-162oC.

References: [1]Patent: EP634413,1995,A1 .

15
[ 936011-18-6 ]
[ 138006-41-4 ]
[ 936011-19-7 ]

Yield	Reaction Conditions	Operation in experiment
	With n-butyllithium; In hexane; di-isopropyl ether; at -78℃; for 0.5h;	To a stirred solution of nBuLi (1.6 M in hexane, 10.4 mL, 16.6 mL) in diisopropyl ether (30 mL) was added <strong>[138006-41-4]3-bromo-2,5-dichloropyridine</strong> (3.78 g, 16.6 mmol) in diisopropylether (10 mL) slowly at -78 0C. The resulting suspension was treated with 2-methoxy-5-vinylisonicotinaldehyde (1.36 g, 8.33 mmol) in diisopropylether (10 mL) and allowed to stir for 30 min at -78 0C followed by warming to room temperature. The mixture was diluted with EtOAc, washed with water and brine, dried (Na2SO4), concentrated, and purified by flash chromatography to afford the title compound. 1H NMR (600 MHz, CDCl3) delta 8.32 (d, IH); 8.25 (s, IH); 7.69 (d, IH); 6.71 (dd, IH); 6.68 (s, IH); 6.21 (s, IH); 5.57 (dd, IH); 5.30 (dd, IH); 3.95 (s, 3H).
	With n-butyllithium; In hexane; di-isopropyl ether; at -78℃; for 0.5h;	Step 3: (2,5-dichloropyridin-3-yl)(2-methoxy-5-vinylpyridin-4-yl)methanol; To a stirred solution of nBuLi (1.6 M in hexane, 10.4 mL, 16.6 mL) in diisopropyl ether (30 mL) was added <strong>[138006-41-4]3-bromo-2,5-dichloropyridine</strong> (3.78 g, 16.6 mmol) in diisopropylether (10 mL) slowly at -78 0C. The resulting suspension was treated with 2-methoxy-5-vinylisonicotinaldehyde (1.36 g, 8.33 mmol) in diisopropylether (10 mL) and allowed to stir for 30 min at -78 0C followed by warming to room temperature. The mixture was diluted with EtOAc, washed with water and brine, dried (Na2SO4), concentrated, and purified by flash chromatography to afford the title compound. 1H NMR (600 MHz, CDCl3) delta 8.32 (d, IH); 8.25 (s, IH); 7.69 (d, IH); 6.71 (dd, IH); 6.68 (s, IH); 6.21 (s, IH); 5.57 (dd, IH); 5.30 (dd, IH); 3.95 (s, 3H).

References: [1]Patent: WO2007/50383,2007,A2 .Location in patent: Page/Page column 58.
[2]Patent: WO2007/50401,2007,A2 .Location in patent: Page/Page column 29; 54; 55.

16
[ 893620-48-9 ]
[ 138006-41-4 ]
[ 936011-14-2 ]

Yield	Reaction Conditions	Operation in experiment
	With n-butyllithium; In tetrahydrofuran; hexane; di-isopropyl ether; at -78℃; for 0.5h;	To a stirred solution of nBuLi (1.6 M in hexane, 5.5 mL, 8.8 mL) in diisopropyl ether (20 mL) was added <strong>[138006-41-4]3-bromo-2,5-dichloropyridine</strong> (2.0 g, 8.8 mmol) in diisopropylether (10 mL) slowly at - 78 0C. The resulting suspension was treated with 2-vinylnicotinaldehyde (1.2 g, 8.8 mmol) in THF (5 mL) and allowed to stir for 30 min at -78 0C followed by warming to room temperature. The mixture was diluted with EtOAc, washed with water and brine, dried (Na2SO4), concentrated, and purified by flash chromatography to afford the title compound. 1H NMR (600 MHz, CDCl3) delta 8.58 (dd, IH); 8.32 (d, IH); 7.83 (d, IH); 7.54 (dd, IH); 7.21 (dd, IH); 7.06 (dd, IH); 6.42 (dd, IH); 6.37 (br s, IH); 5.58 (dd, IH); 2.79 (br s, IH). LRMS (ESI) calc'd for (C13H10Cl2N2O) [M+H]+, 281.0; found 280.7.
	With n-butyllithium; In tetrahydrofuran; hexane; di-isopropyl ether; at -78℃; for 0.5h;	Step 2: (2,5-dichloropyridin-3-yl)(2-vinylpyridin-3-yl)methanol; To a stirred solution of nBuLi (1.6 M in hexane, 5.5 mL, 8.8 mL) in diisopropyl ether (20 mL) was added 3-bromo-2,5-dichlororhoyridine (2.0 g, 8.8 mmol) in diisopropylether (10 mL) slowly at - 78 0C. The resulting suspension was treated with 2-vinylnicotinaldehyde (1.2 g, 8.8 mmol) in THF (5 mL) and allowed to stir for 30 min at -78 0C followed by warming to room temperature. The mixture was diluted with EtOAc, washed with water and brine, dried (Na2SO4), concentrated, and purified by flash chromatography to afford the title compound. 1H NMR (600 MHz, CDCl3) delta 8.58 (dd, IH); 8.32 (d, IH); 7.83 (d, IH); 7.54 (dd, IH); 7.21 (dd, IH); 7.06 (dd, IH); 6.42 (dd, IH); 6.37 (br s, IH); 5.58 (dd, IH); 2.79 (br s, IH). LRMS (ESI) calc'd for (C13HiOCl2N2O) [M+H]+, 281.0; found 280.7.

References: [1]Patent: WO2007/50383,2007,A2 .Location in patent: Page/Page column 54-55.
[2]Patent: WO2007/50401,2007,A2 .Location in patent: Page/Page column 51; 52.

17
[ 138006-41-4 ]
[ 100-51-6 ]
[ 202409-82-3 ]

Yield	Reaction Conditions	Operation in experiment
	With sodium hydride; In N,N-dimethyl-formamide; at 100℃; for 0.75h;Microwave irradiation;	In a microwave tube NaH (60% in paraffin. 56 mg. 1.4 mmol) was washed with hexane and 3-bromo-2.5-dichloro-pyridine (245 mg. 1.08 mmol) in dry DMF (2 mL) were added. To this suspension BnOH (123 muL. 1.23 mmol) in dry DMF (1 mL) was dropped carefully. The reaction mixture was stirred 15 min until the formation of hydrogen has ceased. The tube was sealed and stirred at 100 C in a microwave reactor for 30 min. After removal of the solvent in vacuo the residue was partioned between water (10 mL) and DCM (10 mL) and extracted with DCM (3 x 10 mL). The combined organic fractions were washed with brine, dried overNa2SO4. filtered and concentrated in vacuo. The resulting title compound was used for the next reaction without purification. GC-MS (m/z): 297 [M+] .

References: [1]Patent: WO2008/116620,2008,A1 .Location in patent: Page/Page column 169.

18
[ 50595-15-8 ]
[ 138006-41-4 ]
[ 1240288-29-2 ]

Yield	Reaction Conditions	Operation in experiment
		A solution of 2-te/f-butyl glycolate (437 mg; 3.31 mmol) in anhydrous THF (5 ml.) was treated with NaH (159 mg; 3.97 mmol) and stirred at RT for 10 minutes before treating with a solution of <strong>[138006-41-4]3-bromo-2,5-dichloropyridine</strong> (Matrix; 500 mg; 2.20 mmol) in anhydrous THF (5 ml_). The resulting reaction mixture was stirred for 22 hours. The reaction mixture was treated with a solution of 2-te/f-butyl glycolate (437 mg; 3.31 mmol) in THF (2 ml), then with NaH (159 mg; 3.97 mmol) and the reaction mixture was stirred for 16 h. The reaction was quenched with tBuOH, the sovent removed under reduced pressure affording a brown solid, which was purified by flash column chromatography (silica), eluting with cyclohexane containing increasing amounts of EtOAc, affording the title compound as a yellow sticky solid.1H NMR (300MHz, DMSOd6) delta [ppm] 8.33 (1 H, d, J= 2.3 Hz), 8.21 (1 H, d, J= 2.3 Hz), 4.86 (2H, s), 1.38 (9H, s). HPLC (Condition A) Rt 5.1 min.

References: [1]Patent: WO2010/92043,2010,A1 .Location in patent: Page/Page column 137.

19
[ 138006-41-4 ]
[ 1289151-71-8 ]

References: [1]Patent: WO2012/44531,2012,A1 .

20
[ 138006-41-4 ]
[ 57260-71-6 ]
[ 1289094-51-4 ]

Yield	Reaction Conditions	Operation in experiment
54.4%	With N-ethyl-N,N-diisopropylamine; In 1-methyl-pyrrolidin-2-one; at 160 - 165℃; for 0.25h;	Step Ml. A mixture of tert-butyl piperazine- l-carboxylate (186 mg, 0.996 mmol), 3-bromo- 2,5-dichloropyridine (226mg, 0.996 mmol), and DIEA (174 muEpsilon, 0.996 mmol) in NMP was heated at 160-165 C for 15 min. Silica gel column purification with 5% EtOAc in DCM gave tert-butyl 4-(3-bromo-5-chloropyridin-2-yl)piperazine-l-carboxylate (204mg, 0.542 mmol, 54.4 % yield). White solid. ^- MRCCDCls, 500MHz) delta 8.18 (1H, s), 7.80 (1H, s), 3.58 (4H,m), 3.26(4H,m), 1.49 (9H, s),

References: [1]Patent: WO2012/44531,2012,A1 .Location in patent: Page/Page column 55-56.

21
3-bromo-5-chloropyridine-N-oxide [ No CAS ]
[ 97966-00-2 ]
[ 138006-41-4 ]

References: [1]Organic Letters,2015,vol. 17,p. 2948 - 2951.
[2]Organic Letters,2016,vol. 18,p. 1956 - 1959.

22
[ 107-21-1 ]
[ 138006-41-4 ]
2-((3-bromo-5-chloropyridin-2-yl)oxy)ethan-1-ol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
61%	With 18-crown-6 ether; potassium hydroxide; In toluene; at 120℃; for 4h;	A mixture of ethane-1, - o . g, .93 mmol), 3-bromo-2,5- dichloropyridine (2.47 g, 10.9 mmol), potassium hydroxide (1.22 g, 21.7 mmol), (1170) 1,4,7,10,13,16-hexaoxacyclooctadecane (1.15 g, 4.35 mmol), and toluene (50 mL) was stirred for four hours at 120 C. The mixture was cooled, and diluted with water. The mixture was extracted three times with dichloromethane. The combined organic layers were concentrated, and the resulting residue was purified by MPLC eluting with a gradient of 20-50% ethyl acetate in petroleum ether to afford 2-((3-bromo-5-chloropyridin-2-yl)oxy)ethan-1-ol (1.69 g, 61%) as a colorless oil.

References: [1]Patent: WO2015/171610,2015,A2 .Location in patent: Paragraph 000481.

23
[ 138006-41-4 ]
2-((3-(benzylthio)-5-chloropyridin-2-yl)oxy)ethan-1-ol [ No CAS ]

References: [1]Patent: WO2015/171610,2015,A2 .

24
[ 138006-41-4 ]
2-((3-(benzylthio)-5-chloropyridin-2-yl)oxy)ethyl acetate [ No CAS ]

References: [1]Patent: WO2015/171610,2015,A2 .

25
[ 138006-41-4 ]
2-((5-chloro-3-(chlorosulfonyl)pyridin-2-yl)oxy)ethyl acetate [ No CAS ]

References: [1]Patent: WO2015/171610,2015,A2 .

26
[ 138006-41-4 ]
methyl (S,E)-3-(4-((2-(2-acetoxyethoxy)-5-chloropyridin-3-yl)sulfonyl)-6-(2-(2-chloro-6-fluorophenyl)prop-1-en-1-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)propanoate [ No CAS ]

References: [1]Patent: WO2015/171610,2015,A2 .

27
[ 138006-41-4 ]
methyl (S,E)-3-(4-((5-chloro-2-(2-hydroxyethoxy)pyridin-3-yl)sulfonyl)-6-(2-(2-chloro-6-fluorophenyl)prop-1-en-1-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)propanoate [ No CAS ]

References: [1]Patent: WO2015/171610,2015,A2 .

28
[ 138006-41-4 ]
[ 155742-48-6 ]
4-(((3-bromo-5-chloropyridin-2-yl)oxy)methyl)oxazole [ No CAS ]